In today's episode, we cover some major stories in medical news:

First up, the UK High Court has upheld a ban on puberty blockers for youth with gender dysphoria, citing a lack of evidence for their safety and effectiveness. While trans advocacy groups plan to appeal, the ruling limits use to clinical trials for now.

Next, the European Medicines Agency has rejected a license for a promising new Alzheimer's drug called lacanumab over safety concerns, despite the drug showing ability to slow cognitive decline by 25% in trials. The setback is disappointing for many hoping for a treatment.

Finally, an exciting development on the diagnostic front - a new blood test called AP's-2 has demonstrated over 90% accuracy in diagnosing early-stage Alzheimer's, outperforming primary care doctors. The test could revolutionize early detection if approved.

Today, we're delving into some fascinating topics that could impact your health and well-being. First, we'll explore the promising potential of glycine as a supplement for aging and how it might just be the secret to a longer, healthier life. Next, we tackle the evolving landscape of breast cancer screening in Australia and what a shift to a risk-based approach could mean for women everywhere. Finally, we're pulling apart the popular vaping trend to uncover what's really inside those devices and their alarming environmental impact.

Welcome to MedHeads, the podcast where we bring you the latest and most compelling stories in the medical world. I'm your host, Michelle. Today, we're diving into three pivotal issues making waves in the healthcare community.

First, we uncover the severe physical and mental health challenges faced by Julian Assange during his prolonged isolation, highlighting the harsh impacts of confinement.

Next, we turn our focus to the dire financial crisis in Victoria's healthcare system, where a $1.4 billion deficit is forcing hospitals to take drastic cost-cutting measures, impacting patient care and staff morale.

Finally, we explore the newly approved Alzheimer's drug, Donanumab (Kisunla), stirring both hope and controversy with its potential to slow cognitive decline and its significant risks.